FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3044456704> ?p ?o ?g. }

• W3044456704 endingPage "262" @default.
• W3044456704 startingPage "256" @default.
• W3044456704 abstract "Abstract Objectives This report provides data for the extent of B cell depletion and recovery, efficacy, safety and immunogenicity of Sandoz rituximab (SDZ-RTX; GP2013; Rixathon®) compared with reference rituximab (Ref-RTX) up to week 52 of the ASSIST-RA study. Methods Patients were randomized to SDZ-RTX or Ref-RTX in combination with methotrexate according to the RTX label. The primary endpoint was analysed at week 24. Responders (28-joint DAS [DAS28] decrease from baseline &gt;1.2) at week 24 with residual disease activity (DAS28 ≥2.6) were eligible for a second treatment course between week 24 and 52. Endpoints after week 24 included change from baseline in peripheral B cells, DAS28, ACR 20% response rate (ACR20), Clinical and Simplified Disease Activity Indexes (CDAI, SDAI) and HAQ disability index (HAQ-DI). Safety and immunogenicity were assessed by the incidence of adverse events and antidrug antibodies. Results Primary and secondary endpoints up to week 24 were met. Overall, 260/312 randomized patients completed treatment up to week 52. SDZ-RTX resulted in B cell concentrations over time similar to Ref-RTX. The efficacy of SDZ-RTX was similar to Ref-RTX up to week 52, as measured by DAS28, ACR20/50/70, CDAI, SDAI and HAQ-DI. Safety of SDZ-RTX was similar to Ref-RTX regarding frequency, type and severity of adverse events, which were consistent with the known Ref-RTX safety profile. The incidence of antidrug antibodies was low and transient similarly across treatment groups. Conclusion SDZ-RTX demonstrated similar B cell concentrations over time, efficacy, safety and immunogenicity to Ref-RTX over 52 weeks of the ASSIST-RA study." @default.
• W3044456704 created "2020-07-29" @default.
• W3044456704 creator A5033879584 @default.
• W3044456704 creator A5037872908 @default.
• W3044456704 creator A5057538503 @default.
• W3044456704 creator A5064633070 @default.
• W3044456704 creator A5068353611 @default.
• W3044456704 creator A5071926023 @default.
• W3044456704 creator A5074118915 @default.
• W3044456704 creator A5074627741 @default.
• W3044456704 creator A5082669130 @default.
• W3044456704 creator A5086018261 @default.
• W3044456704 creator A5090753435 @default.
• W3044456704 date "2020-07-23" @default.
• W3044456704 modified "2023-10-16" @default.
• W3044456704 title "Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial" @default.
• W3044456704 cites W2015480191 @default.
• W3044456704 cites W2086286894 @default.
• W3044456704 cites W2096545386 @default.
• W3044456704 cites W2120393706 @default.
• W3044456704 cites W2140790130 @default.
• W3044456704 cites W2142004396 @default.
• W3044456704 cites W2166228239 @default.
• W3044456704 cites W2411832526 @default.
• W3044456704 cites W2574342714 @default.
• W3044456704 cites W2606245581 @default.
• W3044456704 cites W2615840435 @default.
• W3044456704 cites W2720123248 @default.
• W3044456704 cites W2734929604 @default.
• W3044456704 cites W2792050029 @default.
• W3044456704 cites W2802364203 @default.
• W3044456704 cites W2883406108 @default.
• W3044456704 cites W2897350428 @default.
• W3044456704 cites W2917800966 @default.
• W3044456704 doi "https://doi.org/10.1093/rheumatology/keaa234" @default.
• W3044456704 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32699904" @default.
• W3044456704 hasPublicationYear "2020" @default.
• W3044456704 type Work @default.
• W3044456704 sameAs 3044456704 @default.
• W3044456704 citedByCount "15" @default.
• W3044456704 countsByYear W30444567042021 @default.
• W3044456704 countsByYear W30444567042022 @default.
• W3044456704 countsByYear W30444567042023 @default.
• W3044456704 crossrefType "journal-article" @default.
• W3044456704 hasAuthorship W3044456704A5033879584 @default.
• W3044456704 hasAuthorship W3044456704A5037872908 @default.
• W3044456704 hasAuthorship W3044456704A5057538503 @default.
• W3044456704 hasAuthorship W3044456704A5064633070 @default.
• W3044456704 hasAuthorship W3044456704A5068353611 @default.
• W3044456704 hasAuthorship W3044456704A5071926023 @default.
• W3044456704 hasAuthorship W3044456704A5074118915 @default.
• W3044456704 hasAuthorship W3044456704A5074627741 @default.
• W3044456704 hasAuthorship W3044456704A5082669130 @default.
• W3044456704 hasAuthorship W3044456704A5086018261 @default.
• W3044456704 hasAuthorship W3044456704A5090753435 @default.
• W3044456704 hasConcept C120665830 @default.
• W3044456704 hasConcept C121332964 @default.
• W3044456704 hasConcept C126322002 @default.
• W3044456704 hasConcept C159654299 @default.
• W3044456704 hasConcept C168563851 @default.
• W3044456704 hasConcept C197934379 @default.
• W3044456704 hasConcept C203014093 @default.
• W3044456704 hasConcept C203092338 @default.
• W3044456704 hasConcept C2777575956 @default.
• W3044456704 hasConcept C2779338263 @default.
• W3044456704 hasConcept C2780653079 @default.
• W3044456704 hasConcept C2780868878 @default.
• W3044456704 hasConcept C2781059491 @default.
• W3044456704 hasConcept C3018359032 @default.
• W3044456704 hasConcept C61511704 @default.
• W3044456704 hasConcept C71924100 @default.
• W3044456704 hasConcept C90924648 @default.
• W3044456704 hasConceptScore W3044456704C120665830 @default.
• W3044456704 hasConceptScore W3044456704C121332964 @default.
• W3044456704 hasConceptScore W3044456704C126322002 @default.
• W3044456704 hasConceptScore W3044456704C159654299 @default.
• W3044456704 hasConceptScore W3044456704C168563851 @default.
• W3044456704 hasConceptScore W3044456704C197934379 @default.
• W3044456704 hasConceptScore W3044456704C203014093 @default.
• W3044456704 hasConceptScore W3044456704C203092338 @default.
• W3044456704 hasConceptScore W3044456704C2777575956 @default.
• W3044456704 hasConceptScore W3044456704C2779338263 @default.
• W3044456704 hasConceptScore W3044456704C2780653079 @default.
• W3044456704 hasConceptScore W3044456704C2780868878 @default.
• W3044456704 hasConceptScore W3044456704C2781059491 @default.
• W3044456704 hasConceptScore W3044456704C3018359032 @default.
• W3044456704 hasConceptScore W3044456704C61511704 @default.
• W3044456704 hasConceptScore W3044456704C71924100 @default.
• W3044456704 hasConceptScore W3044456704C90924648 @default.
• W3044456704 hasFunder F4320307770 @default.
• W3044456704 hasFunder F4320309529 @default.
• W3044456704 hasIssue "1" @default.
• W3044456704 hasLocation W30444567041 @default.
• W3044456704 hasOpenAccess W3044456704 @default.
• W3044456704 hasPrimaryLocation W30444567041 @default.
• W3044456704 hasRelatedWork W1977601919 @default.
• W3044456704 hasRelatedWork W2026202749 @default.
• W3044456704 hasRelatedWork W2068695759 @default.

• next